ORIC Pharmaceuticals, Inc.
ORIC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $1 | $0 | $0 |
| Gross Profit | -$1 | -$1 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $114 | $85 | $62 | $57 |
| G&A Expenses | $29 | $26 | $25 | $22 |
| SG&A Expenses | $29 | $26 | $25 | $22 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1 | -$1 | $5 | $0 |
| Operating Expenses | $142 | $110 | $92 | $79 |
| Operating Income | -$143 | -$111 | -$92 | -$79 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $15 | $10 | $3 | $0 |
| Pre-Tax Income | -$128 | -$101 | -$89 | -$79 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$128 | -$101 | -$89 | -$79 |
| % Margin | – | – | – | – |
| EPS | -1.83 | -1.96 | -2.25 | -2.07 |
| % Growth | 6.6% | 12.9% | -8.7% | – |
| EPS Diluted | -1.83 | -1.96 | -2.25 | -2.07 |
| Weighted Avg Shares Out | 70 | 51 | 40 | 38 |
| Weighted Avg Shares Out Dil | 70 | 51 | 40 | 38 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $10 | $3 | $0 |
| Interest Expense | $0 | $0 | $3 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$127 | -$110 | -$86 | -$78 |
| % Margin | – | – | – | – |